|TABLE OF CONTENTSCluster's lifeOur member's newsSave the dateCalls for projectsAround our themes|
2016 ends in beauty and we wish you a year full of projects for 2017.
The beginning of the year 2017 will be more connected at Lyonbiopole...
We will meet you in early January for more information!
|8th edition of the Nosocomial Infections DayThis edition of the Nosocomial Infections Day was organized by Lyonbiopole and Finovi. 75 participants representing academic, clinic and industrial communities were gathered and were able to connect with perspectives of potential future collaborations in mind. 3 topics have been tackled: bacterial genomics, innovative therapeutic approaches and new vaccine approaches. [...]|
|Lyonbiopole members rewarded at the 2016 Innovation TrophiesDuring the 11th edition of the Innovation Trophies of Bref Eco, two Lyonbiopole member companies were rewarded: Noveal e-santé and Theranexus. [...]|
|New memberMdp designs micro-electric motor solutions for the medical market and develops, thanks to its integrated mechatronics engineering department, undeniable know-how in the development of medical devices incorporating electric micro-motors. [...]|
|New memberMessenger Biopharma is a French biotech company dedicated to research on messenger RNA. This latter is taken up by cells, in vivo as well as ex vivo, in human or animals, in order to immunize them or to treat numerous diseases. [...]|
|Focus onThe University of Utah has awarded a subcontract to SynapCell as part of the NIH/NINDS Epilepsy Therapy Screening Program (ETSP). [...]|
|Décember 2nd, 2016Imaxio sells Trolovol®||Décember 2nd, 2016ERYTECH presents new data||Décember 7th, 2016PDC*line Pharma raises ¤4 million|
|Décember 9th, 2016EDAP Receives the Prestigious Prix Galien||Décember 14th, 2016Valneva starts clinical testing of Lyme disease vaccine||Décember 16th, 2016ElsaLys Biotech acquires rights of Transgene's anti-CD115 antibody|
|Décember 19th, 2016Adocia and Lilly announce completion of an insulin pump study||Décember 19th, 2016ENYO Pharma SA announces initiation of the Phase 1 clinical programme with EYP001||Décember 19th, 2016EDAP Reports Superior Outcomes of Focal Ablatherm-HIFU Compared to Robotic Radical Prostatectomy|
|Décember 20th, 2016Three Novasep custom manufacturing sites renew FDA approval in 2016||Décember 21th, 2016Enyo Pharma receives a ¤2.5 million grant|
EUROPE & INTERNATIONAL
Before January 16th, 2017
Before March 16th, 2017
Before April 11th, 2017
Before November 8th, 2017
May 16th, 2017
September 24th, 2017
321, avenue Jean Jaurès
Tel. : +33 (0)4 72 76 53 30
Fax : +33 (0)9 55 91 30 26
This email has been sent automatically to [[EMAIL_TO]]. Click here to unsubscribe.